{"id":"https://openalex.org/W2027198501","doi":"https://doi.org/10.1001/archpsyc.59.5.441","title":"A Double-blind, Placebo-Controlled Dose-Response Comparison of Intramuscular Olanzapine and Haloperidol in the Treatment of Acute Agitation in Schizophrenia","display_name":"A Double-blind, Placebo-Controlled Dose-Response Comparison of Intramuscular Olanzapine and Haloperidol in the Treatment of Acute Agitation in Schizophrenia","publication_year":2002,"publication_date":"2002-05-01","ids":{"openalex":"https://openalex.org/W2027198501","doi":"https://doi.org/10.1001/archpsyc.59.5.441","mag":"2027198501","pmid":"https://pubmed.ncbi.nlm.nih.gov/11982448"},"language":"en","primary_location":{"id":"doi:10.1001/archpsyc.59.5.441","doi":"https://doi.org/10.1001/archpsyc.59.5.441","is_oa":false,"landing_page_url":"https://doi.org/10.1001/archpsyc.59.5.441","pdf_url":null,"source":{"id":"https://openalex.org/S126359496","display_name":"Archives of General Psychiatry","issn_l":"0003-990X","issn":["0003-990X","1538-3636"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4310320259","host_organization_name":"American Medical Association","host_organization_lineage":["https://openalex.org/P4310320259"],"host_organization_lineage_names":["American Medical Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Archives of General Psychiatry","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5110607987","display_name":"Alan F. Breier","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alan Breier","raw_affiliation_strings":["Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, DC 1748, Indianapolis, IN 46285, USA. Breier_Alan@lilly.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, DC 1748, Indianapolis, IN 46285, USA. Breier_Alan@lilly.com","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039416113","display_name":"Karena Meehan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183935753","display_name":"King's College London","ror":"https://ror.org/0220mzb33","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I183935753"]},{"id":"https://openalex.org/I200323923","display_name":"South London and Maudsley NHS Foundation Trust","ror":"https://ror.org/015803449","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I200323923"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Karena Meehan","raw_affiliation_strings":["King's College London","South London and Maudsley NHS Foundation Trust"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"King's College London","institution_ids":["https://openalex.org/I183935753"]},{"raw_affiliation_string":"South London and Maudsley NHS Foundation Trust","institution_ids":["https://openalex.org/I200323923"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074883362","display_name":"Martin A. Birkett","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Martin Birkett","raw_affiliation_strings":["Eli-Lilly"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli-Lilly","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108527133","display_name":"Stacy R. David","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stacy David","raw_affiliation_strings":["Eli-Lilly"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli-Lilly","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070773963","display_name":"Iris Ferchland","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Iris Ferchland","raw_affiliation_strings":["Eli-Lilly"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli-Lilly","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028823663","display_name":"Virginia K. Sutton","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Virginia Sutton","raw_affiliation_strings":["Eli-Lilly"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli-Lilly","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075562229","display_name":"Cindy Coe Taylor","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Cindy C. Taylor","raw_affiliation_strings":["Eli-Lilly"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli-Lilly","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085677388","display_name":"Rebecca L. Palmer","orcid":"https://orcid.org/0000-0002-0827-4706","observed_orcids":["https://orcid.org/0000-0002-0827-4706"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rebecca Palmer","raw_affiliation_strings":["Eli-Lilly"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli-Lilly","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002615049","display_name":"Martin R.K Dossenbach","orcid":"https://orcid.org/0009-0006-6128-4002","observed_orcids":["https://orcid.org/0009-0006-6128-4002"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Martin Dossenbach","raw_affiliation_strings":["#N##TAB##TAB##TAB##TAB# Eli Lilly and Company#N##TAB##TAB##TAB#"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"#N##TAB##TAB##TAB##TAB# Eli Lilly and Company#N##TAB##TAB##TAB#","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059829414","display_name":"G.M. Kiesler","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Geri Kiesler","raw_affiliation_strings":["Eli-Lilly"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli-Lilly","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113530408","display_name":"Shlomo Brook","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I192619145","display_name":"University of the Witwatersrand","ror":"https://ror.org/03rp50x72","country_code":"ZA","type":"education","lineage":["https://openalex.org/I192619145"]}],"countries":["ZA"],"is_corresponding":false,"raw_author_name":"Shlomo Brook","raw_affiliation_strings":["university of the Witwatersrand"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"university of the Witwatersrand","institution_ids":["https://openalex.org/I192619145"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5110021344","display_name":"P\u00e1draig Wright","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I183935753","display_name":"King's College London","ror":"https://ror.org/0220mzb33","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I183935753"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"Padraig Wright","raw_affiliation_strings":["Eli Lilly","King's College London"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly","institution_ids":["https://openalex.org/I168537998"]},{"raw_affiliation_string":"King's College London","institution_ids":["https://openalex.org/I183935753"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":11.3116,"has_fulltext":false,"cited_by_count":289,"citation_normalized_percentile":{"value":0.99044393,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":94,"max":100},"biblio":{"volume":"59","issue":"5","first_page":"441","last_page":"441"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13944","display_name":"Psychiatric care and mental health services","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/3203","display_name":"Clinical Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11921","display_name":"Electroconvulsive Therapy Studies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/haloperidol","display_name":"haloperidol","score":0.9430000185966492},{"id":"https://openalex.org/keywords/acute-agitation","display_name":"acute agitation","score":0.9369999766349792},{"id":"https://openalex.org/keywords/schizophrenia","display_name":"schizophrenia","score":0.9950000047683716},{"id":"https://openalex.org/keywords/atypical-antipsychotics","display_name":"atypical antipsychotics","score":0.8740000128746033},{"id":"https://openalex.org/keywords/dose-response-relationship","display_name":"dose-response relationship","score":0.8510000109672546},{"id":"https://openalex.org/keywords/intramuscular-injection","display_name":"intramuscular injection","score":0.6430000066757202},{"id":"https://openalex.org/keywords/parkinsonism","display_name":"parkinsonism","score":0.7450000047683716},{"id":"https://openalex.org/keywords/extrapyramidal-symptoms","display_name":"extrapyramidal symptoms","score":0.890999972820282},{"id":"https://openalex.org/keywords/hypotension","display_name":"hypotension","score":0.8069999814033508},{"id":"https://openalex.org/keywords/qtc-interval","display_name":"QTc interval","score":0.859000027179718},{"id":"https://openalex.org/keywords/hospitalized-patients","display_name":"hospitalized patients","score":0.5419999957084656},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.48100000619888306}],"concepts":[{"id":"https://openalex.org/C2776619155","wikidata":"https://www.wikidata.org/wiki/Q201872","display_name":"Olanzapine","level":3,"score":0.9694746136665344},{"id":"https://openalex.org/C2780948584","wikidata":"https://www.wikidata.org/wiki/Q251347","display_name":"Haloperidol","level":3,"score":0.8585994839668274},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.7718287110328674},{"id":"https://openalex.org/C2780135775","wikidata":"https://www.wikidata.org/wiki/Q7233251","display_name":"Positive and Negative Syndrome Scale","level":3,"score":0.7044413685798645},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.654686450958252},{"id":"https://openalex.org/C2780494398","wikidata":"https://www.wikidata.org/wiki/Q208144","display_name":"Antipsychotic","level":3,"score":0.6499861478805542},{"id":"https://openalex.org/C2781353949","wikidata":"https://www.wikidata.org/wiki/Q3271533","display_name":"Dopamine antagonist","level":4,"score":0.5997236967086792},{"id":"https://openalex.org/C2780616385","wikidata":"https://www.wikidata.org/wiki/Q1385411","display_name":"Extrapyramidal symptoms","level":4,"score":0.5993637442588806},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5619757771492004},{"id":"https://openalex.org/C2776921671","wikidata":"https://www.wikidata.org/wiki/Q758295","display_name":"Atypical antipsychotic","level":4,"score":0.5574037432670593},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.5391839146614075},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5016589164733887},{"id":"https://openalex.org/C2777393122","wikidata":"https://www.wikidata.org/wiki/Q416417","display_name":"Akathisia","level":4,"score":0.49243173003196716},{"id":"https://openalex.org/C2776291583","wikidata":"https://www.wikidata.org/wiki/Q432083","display_name":"Intramuscular injection","level":2,"score":0.4737045466899872},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.3907616436481476},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.33187001943588257},{"id":"https://openalex.org/C2779727114","wikidata":"https://www.wikidata.org/wiki/Q170082","display_name":"Psychosis","level":2,"score":0.2781897783279419},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.21521443128585815},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.07133686542510986},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000077152","descriptor_name":"Olanzapine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000208","descriptor_name":"Acute Disease","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001569","descriptor_name":"Benzodiazepines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006220","descriptor_name":"Haloperidol","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D006220","descriptor_name":"Haloperidol","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007273","descriptor_name":"Injections, Intramuscular","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010890","descriptor_name":"Pirenzepine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D010890","descriptor_name":"Pirenzepine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D010890","descriptor_name":"Pirenzepine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D010919","descriptor_name":"Placebos","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011569","descriptor_name":"Psychiatric Status Rating Scales","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011595","descriptor_name":"Psychomotor Agitation","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012559","descriptor_name":"Schizophrenia","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D012559","descriptor_name":"Schizophrenia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012565","descriptor_name":"Schizophrenic Psychology","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1001/archpsyc.59.5.441","doi":"https://doi.org/10.1001/archpsyc.59.5.441","is_oa":false,"landing_page_url":"https://doi.org/10.1001/archpsyc.59.5.441","pdf_url":null,"source":{"id":"https://openalex.org/S126359496","display_name":"Archives of General Psychiatry","issn_l":"0003-990X","issn":["0003-990X","1538-3636"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4310320259","host_organization_name":"American Medical Association","host_organization_lineage":["https://openalex.org/P4310320259"],"host_organization_lineage_names":["American Medical Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Archives of General Psychiatry","raw_type":"journal-article"},{"id":"pmid:11982448","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11982448","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Archives of general psychiatry","raw_type":"Clinical Trial"},{"id":"pmh:oai:kclpure.kcl.ac.uk:publications/a452bdec-3ed9-402c-bd54-93c1cc315d3d","doi":null,"is_oa":false,"landing_page_url":"https://kclpure.kcl.ac.uk/portal/en/publications/a452bdec-3ed9-402c-bd54-93c1cc315d3d","pdf_url":null,"source":{"id":"https://openalex.org/S4306400216","display_name":"Research Portal (King's College London)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I183935753","host_organization_name":"King's College London","host_organization_lineage":["https://openalex.org/I183935753"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Breier, A, Meehan, K, Birkett, M, David, S, Ferchland, I, Sutton, V, Taylor, C C, Palmer, R, Dossenbach, M, Kiesler, G, Brook, S & Wright, P 2002, 'A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia', Archives of General Psychiatry, vol. 59, no. 5, pp. 441 - 448. https://doi.org/10.1001/archpsyc.59.5.441","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":50,"referenced_works":["https://openalex.org/W72235391","https://openalex.org/W196523845","https://openalex.org/W569513280","https://openalex.org/W1569669859","https://openalex.org/W1587315543","https://openalex.org/W1639136703","https://openalex.org/W1865123885","https://openalex.org/W1869588275","https://openalex.org/W1930368778","https://openalex.org/W1938790275","https://openalex.org/W1972963574","https://openalex.org/W1976175860","https://openalex.org/W1979656037","https://openalex.org/W1983133139","https://openalex.org/W1986688979","https://openalex.org/W1991864854","https://openalex.org/W1992083518","https://openalex.org/W1992882666","https://openalex.org/W1993668511","https://openalex.org/W1999689270","https://openalex.org/W2013951122","https://openalex.org/W2014714354","https://openalex.org/W2022528197","https://openalex.org/W2027471441","https://openalex.org/W2028405482","https://openalex.org/W2030363914","https://openalex.org/W2037426360","https://openalex.org/W2049728968","https://openalex.org/W2059011511","https://openalex.org/W2069837065","https://openalex.org/W2078520799","https://openalex.org/W2095984135","https://openalex.org/W2132071570","https://openalex.org/W2147174308","https://openalex.org/W2150000105","https://openalex.org/W2162144610","https://openalex.org/W2164153892","https://openalex.org/W2165379748","https://openalex.org/W2170280946","https://openalex.org/W2213525860","https://openalex.org/W2216159106","https://openalex.org/W2418029701","https://openalex.org/W2419576777","https://openalex.org/W2428347561","https://openalex.org/W2434519838","https://openalex.org/W2435955692","https://openalex.org/W2517346518","https://openalex.org/W3090293687","https://openalex.org/W4234482488","https://openalex.org/W4297938889"],"related_works":["https://openalex.org/W2171532531","https://openalex.org/W2070087463","https://openalex.org/W2074474323","https://openalex.org/W2005263128","https://openalex.org/W2066057833","https://openalex.org/W2001912971","https://openalex.org/W2103338429","https://openalex.org/W2004379873","https://openalex.org/W2504827788","https://openalex.org/W1990659863"],"abstract_inverted_index":{"BACKGROUND:":[0],"An":[1],"intramuscular":[2],"(IM)":[3],"formulation":[4],"of":[5,53,78,145,190,196,241,263,279,294],"olanzapine":[6,54,74,146,173,181,197,265,275],"has":[7],"been":[8],"developed":[9],"because":[10],"there":[11],"are":[12],"no":[13,214],"rapid-acting":[14],"IM":[15,51,73,247,264],"atypical":[16],"antipsychotic":[17],"drugs":[18],"currently":[19],"available":[20],"in":[21,29,75,86,131,202,232,290,297],"the":[22,76,84,99,120,142,209,221,233,291],"United":[23],"States":[24],"for":[25,72,129,178,219,228],"treating":[26],"acute":[27,295],"agitation":[28,79,132,203,296],"patients":[30,38,298],"with":[31,39,110,167,185,246,251,268,299],"schizophrenia.":[32],"METHODS:":[33],"Recently":[34],"hospitalized":[35],"acutely":[36],"agitated":[37],"schizophrenia":[40,300],"(N":[41],"=":[42,149,153,157,161],"270)":[43],"were":[44,163,213],"randomized":[45],"to":[46,49,165,281],"receive":[47],"1":[48],"3":[50],"injections":[52],"(2.5,":[55],"5.0,":[56,191],"7.5,":[57,192],"or":[58,64,193,227,258,267],"10.0":[59,159,194,282],"mg),":[60,63],"haloperidol":[61,186,248],"(7.5":[62],"placebo":[65,168,205,269],"within":[66],"24":[67,117],"hours.":[68],"A":[69,188],"dose-response":[70,127,288],"relationship":[71,128,289],"reduction":[77,85,130,201],"was":[80,103,237],"assessed":[81,104],"by":[82,105],"measuring":[83],"Positive":[87],"and":[88,109,114,301],"Negative":[89],"Syndrome":[90],"Scale":[91],"Excited":[92],"Component":[93],"(PANSS-EC)":[94],"scores":[95],"2":[96,139],"hours":[97,118,140],"after":[98,119,141,208],"first":[100,121,143,210],"injection.":[101,122,211],"Safety":[102],"recording":[106],"adverse":[107,225],"events":[108],"extrapyramidal":[111],"symptom":[112],"scales":[113],"electrocardiograms":[115],"at":[116,174,276],"RESULTS:":[123],"Olanzapine":[124],"exhibited":[125],"a":[126,199,238,277,287,303],"(F(1,179)=":[133],"14.4;":[134],"P<.001).":[135],"Mean":[136],"PANSS-EC":[137],"reductions":[138],"injection":[144,285],"(2.5":[147],"mg":[148,152,156,160,195,260,283],"-5.5;":[150],"5.0":[151,255],"-8.1;":[154],"7.5":[155,259],"-8.7;":[158],"-9.4)":[162],"superior":[164],"those":[166],"(-2.9;":[169],"P":[170],"=.01":[171],"vs":[172],"2.5":[175,252,280],"mg;":[176],"P<.001":[177],"each":[179],"other":[180],"dose)":[182],"but":[183],"not":[184],"(-7.5).":[187],"dose":[189,278],"caused":[198],"greater":[200,239],"than":[204,250],"30":[206],"minutes":[207],"There":[212,236],"differences":[215],"between":[216],"treatment":[217,245,293],"groups":[218],"hypotension,":[220],"most":[222],"frequently":[223],"reported":[224],"event,":[226],"clinically":[229],"relevant":[230],"changes":[231],"QTc":[234],"interval.":[235],"incidence":[240],"treatment-emergent":[242],"parkinsonism":[243],"during":[244],"(16.7%)":[249],"(P":[253,256,261,271],"=.03),":[254,257],"=.01)":[262],"(0%)":[266,270],"=.01).":[272],"CONCLUSIONS:":[273],"Intramuscular":[274],"per":[284],"exhibits":[286],"rapid":[292],"demonstrates":[302],"favorable":[304],"safety":[305],"profile.":[306]},"counts_by_year":[{"year":2026,"cited_by_count":6},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":10},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":13},{"year":2020,"cited_by_count":6},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":15},{"year":2017,"cited_by_count":7},{"year":2016,"cited_by_count":10},{"year":2015,"cited_by_count":10},{"year":2014,"cited_by_count":16},{"year":2013,"cited_by_count":14},{"year":2012,"cited_by_count":16}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}